

July 8, 2008

U.S. Nuclear Regulatory Commission  
Region III  
Materials Licensing Branch  
2443 Warrenville Road, Suite 210  
Lisle, Illinois 60532

Re: Amendment to 13-32129-01

Dear Madam or Sir:

We wish to amend our Materials License 13-32129-01 as follows:

**DELETE AUTHORIZED USERS**

Please delete the following authorized physician users from our Materials License. They are no longer affiliated with our facility.

Alan S. Cooperman, D.O.  
Marvin D. Walker, D.O.

**ADD AUTHORIZED USERS**

Please add the following authorized physician users to our Materials License. In support of this request we have enclosed a copy of Materials License 13-01535-01 which lists each as an authorized user.


Sandeep S. Ahluwalia, M.D.	for 35.100 and 35.200
James A. Arata, M.D.	for 35.100 and 35.200
John L. Bormann, M.D.	for 35.100 and 35.200
Diane D. Daly, M.D.	for 35.100 and 35.200
Joseph R. DeCamp, M.D.	for 35.100 and 35.200
Brett A. Hagedorn, M.D.	for 35.100 and 35.200
David B. Janizek, M.D.	for 35.100 and 35.200
Shawn M. Johnson, M.D.	for 35.100 and 35.200
Shilpa Kashyap, M.D.	for 35.100 and 35.200
Brian J. Kim, M.D.	for 35.100 and 35.200
John R. Kim, M.D.	for 35.100 and 35.200
John N. Pasalich, M.D.	for 35.100 and 35.200
Dakshesh S. Patel, M.D.	for 35.100 and 35.200
Stephen R. Phillipp, M.D.	for 35.100 and 35.200
Randall J. Phillips, M.D.	for 35.100 and 35.200
John C. Rock, M.D.	for 35.100 and 35.200
Richard W. Sibley, M.D.	for 35.100 and 35.200

RECEIVED JUL 15 2008

Richard P. Stephens, Jr., M.D.	for 35.100 and 35.200
Andre B. Stovall, M.D.	for 35.100 and 35.200
Pamela L. Strange, M.D.	for 35.100 and 35.200
Marc A. Thomas, M.D.	for 35.100 and 35.200
Christine A. Tremper, M.D.	for 35.100 and 35.200
Fred N. Vandeman, M.D.	for 35.100 and 35.200
James C. Wehrenberg, M.D.	for 35.100 and 35.200

If you have any questions or concerns regarding this amendment application, please contact our Medical Nuclear Physicist, Thomas M. Kumpuris, M.D., DABR of Medical Physics Consultants, Inc. 800.321.2207 and / or [tkumpuris@mpcphysics.com](mailto:tkumpuris@mpcphysics.com).

Sincerely,



Joan Darr, Interim Chief Executive Officer

NRC FORM 374


U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 5 PAGES  
Amendment No. 58

MATERIALS LICENSE

In accordance with the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. QHG of Indiana, Inc.</p> <p>2. 7950 West Jefferson Blvd. Fort Wayne, IN 46804-1677</p>	<p>In accordance with letter dated <b>October 15, 2007</b>,</p> <p>3. License number 13-01535-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date <b>June 30, 2015</b></p> <p>Docket No. 030-01594 Reference No.</p>
--	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 25.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p> <p>E. Any byproduct material permitted by 10 CFR 35.500</p>	<p>7. Chemical and/or physical form</p> <p>Any</p>  <p>Sealed Sources (North American Scientific, Inc., Model MED 3601; MED 3630; Draximage, Inc., Brachyseed Model CS-4; Best Industries, Model 230; Implant Sciences Corp., I-Plant, Model 3500; IsoAid, LLC, Model IAI-125A; Mills Biopharmaceuticals, Inc., Models SL-125, SH-125; Bard Model STM1251; Best Medical International Inc., Model 2335 and Theragenics Corp. Theraseed, Model 200.)</p> <p>E. Sealed Sources (North American Scientific, Inc., Models MED 3601 and Du Pont Merck Pharmaceutical Company NES-8412)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed, not to exceed 1 Curie of Iodine-131</p> <p>D. 1 Curie</p> <p>E. 300 millicuries per source and 1200 millicuries total</p>
--	--	--

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
13-01535-01

Docket or Reference Number  
030-01594

Amendment No. 58

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

F. Any byproduct material permitted by 10 CFR 31.11

F. Prepackaged Kits

F. 1 millicurie

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.400.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. Any manual brachytherapy procedure permitted by 10 CFR 35.500.

E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).

F. In vitro studies.



10. Licensed material may be used or stored only at the licensee's facilities located at 7950 West Jefferson Boulevard, Fort Wayne, Indiana.

11. The Radiation Safety Officer for this license is Randall J. Phillips, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Brett A. Hagedorn, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

John Rock, M.D.

10 CFR 35.100, 35.200 and 31.11.

Rik Stephens, M.D.

10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11.

James C. Wehrenberg, M.D.

10 CFR 35.100, 35.200, 35.500 and 31.11.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
13-01535-01


Docket or Reference Number  
030-01594

Amendment No. 58

Authorized Users

Material and Use

James A. Arata, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11.
David B. Janizek, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11.
Christine Anne Tremper, M.D.	10 CFR 35.100, 35.200, 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries) and 35.500.
Randall J. Phillips, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11.
John Pasalich, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Stephen R. Phillip, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Marc Thomas, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Diane D. Daly, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
John L. Bormann, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Michael E. Parker, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Pamela Lee Strange, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Michael W. Tanksley, M.D.	10 CFR 35.100, 35.200, 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries) and 35.500.
Joseph R. Decamp, M.D.	10 CFR 35.100, 35.200, 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries) and 35.500.
John R. Kim, M.D.	10 CFR 35.100, 35.200, 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries) and 35.500.
Frederick N. Vandeman, M.D.	10 CFR 35.100, 35.200, 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities equal to or less than 33 millicuries) and 35.500.
Andre Byard Stovall, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Christopher Michael Kowalski, M.D.	10 CFR 35.100, 35.200 and 35.500.
Richard W. Sibley, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500
Dakshesh S. Patel, M.D.	10 CFR 35.100, 35.200 and 35.500.
Eric V. Heatwole, M.D.	10 CFR 35.100, 35.200 and 35.500.



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
**13-01535-01**

Docket or Reference Number  
**030-01594**

Amendment No. 58

Authorized Users

Material and Use

Shilpa Kashyap, M.D.	10 CFR 35.100, 35.200 and 35.500.
Deepchand Bajpai, M.D.	10 CFR 35.300 and 35.400.
Rao V. P. Mantravadi, M.D.	10 CFR 35.300 and 35.400.
Marc Apple, M.D.	10 CFR 35.400.
Stephen Beyer, M.D.	10 CFR 35.300.
Brian Kim, M.D.	10 CFR 35.100 and 35.200.
Shawn Johnson, M.D.	10 CFR 35.100, 35.200, 35.300
Sandeep S. Ahluwalia, M.D.	10 CFR 35.100 and 35.200.
John C. Lacunza, M.D.	10 CFR 35.100 and 35.200.



- 13. In addition to the possession limits, the licensee shall further restrict the possession of licensed material to quantities and forms specified in 10 CFR 30.35(d) for establishing decommissioning financial obligations.
- 14. The licensee is authorized to transport material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
**13-01535-01**

Docket or Reference Number  
**030-01594**

Amendment No. 58

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated November 16, 2004; and
- B. Facsimiles dated May 10, 2005 and September 20, 2007; and
- C. Letter dated June 28, 2007.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

ate JAN 25 2008

By Colleen Carol Casey  
 Colleen Carol Casey  
 Materials Licensing Branch  
 Region III

From: Origin ID: WWSA (574)267-3200  
 Jeremy Golden  
 Kosciusko Community Hospital  
 2101 DuBois Dr

Warsaw, IN 46580



CL5853088/2124

Ship Date: 14JUL08  
 ActWgt: 1 LB  
 System#: 8385925/INET8061  
 Account#: S \*\*\*\*\*

Delivery Address Bar Code



Ref # 728  
 Invoice #  
 PO #  
 Dept #


SHIP TO: 0000000000 **BILL SENDER**  
**MATERIALS LICENSING BRANCH**  
**U.S. NUCLEAR REGULATORY COMMISSION**  
**2443 WARRENVILLE RD STE 210**

**LISLE, IL 605324352**

**TUE - 15JUL A2**

TRK# 7989 7841 6504  
 0201

**FIRST OVERNIGHT**



**N1 ENLA**

**60532**  
**IL-US**  
**ORD**



**After printing this label:**

1. Use the 'Print' button on this page to print your label to your laser or inkjet printer.
2. Fold the printed page along the horizontal line.
3. Place label in shipping pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.

**Warning:** Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional billing charges, along with the cancellation of your FedEx account number.

Use of this system constitutes your agreement to the service conditions in the current FedEx Service Guide, available on fedex.com. FedEx will not be responsible for any claim in excess of \$100 per package, whether the result of loss, damage, delay, non-delivery, misdelivery, or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim. Limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic value of the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental, consequential, or special is limited to the greater of \$100 or the authorized declared value. Recovery cannot exceed actual documented loss. Maximum for items of extraordinary value is \$500, e.g. jewelry, precious metals, negotiable instruments and other items listed in our Service Guide. Written claims must be filed within strict time limits, see current FedEx Service Guide.